Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9825MR)

This product GTTS-WQ9825MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9825MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ101MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ2086MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ11555MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ13809MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ9471MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ127MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ15240MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ10490MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW